$-0.13 EPS Expected for Aptose Biosciences Inc. (APTO)

March 21, 2018 - By Maria Brooks

 $ 0.13 EPS Expected for Aptose Biosciences Inc. (APTO)

Analysts expect Aptose Biosciences Inc. (NASDAQ:APTO) to report $-0.13 EPS on March, 27 after the close.They anticipate $0.06 EPS change or 31.58 % from last quarter’s $-0.19 EPS. After having $-0.11 EPS previously, Aptose Biosciences Inc.’s analysts see 18.18 % EPS growth. The stock increased 3.44% or $0.12 during the last trading session, reaching $3.76. About 250,880 shares traded. Aptose Biosciences Inc. (NASDAQ:APTO) has declined 60.81% since March 21, 2017 and is downtrending. It has underperformed by 77.51% the S&P500.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Coverage

Among 5 analysts covering Aptose Biosciences (NASDAQ:APTO), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Aptose Biosciences had 15 analyst reports since August 7, 2015 according to SRatingsIntel. On Thursday, September 7 the stock rating was upgraded by H.C. Wainwright to “Buy”. As per Wednesday, November 11, the company rating was maintained by RBC Capital Markets. The firm has “Hold” rating by H.C. Wainwright given on Thursday, June 8. TH Capital downgraded the stock to “Neutral” rating in Friday, November 20 report. Roth Capital upgraded Aptose Biosciences Inc. (NASDAQ:APTO) on Monday, June 13 to “Buy” rating. As per Friday, November 20, the company rating was downgraded by Roth Capital. Zacks upgraded the shares of APTO in report on Friday, August 7 to “Hold” rating. On Wednesday, August 9 the stock rating was maintained by H.C. Wainwright with “Hold”. On Wednesday, November 15 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, November 16.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $109.98 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.